You are here
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
Phone: (803) 576-5684
Email: mcinnes@sccp.sc.edu
Phone: (803) 338-6340
Email: mcinnes@ppipharma.com
Address:
Phone: () -
Type: Nonprofit College or University
DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. This will be accomplished through application of this methodology to the discovery and characterization of new drug-like small molecule therapeutics disrupting interactions relevant to anti-cancer therapy. Improved strategies for developing pharmaceuticals based on inhibitors of protein-protein interactions would be beneficial in order to overcome the limitations ofthe majority of currently druggable targets to those involving ligand-receptor and enzyme-substrate interactions. We will focus our efforts on the Cyclin Dependent Kinase substrate recruitment site as a validated antitumor drug target. Through this si
* Information listed above is at the time of submission. *